Evofem Biosciences Stock Forecast, Price & News

+0.04 (+3.64 %)
(As of 06/21/2021 02:15 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume323,970 shs
Average Volume8.51 million shs
Market Capitalization$117.23 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive EVFM News and Ratings via Email

Sign-up to receive the latest news and ratings for Evofem Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Evofem Biosciences logo

About Evofem Biosciences

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. It has a collaboration agreement with National Community Oncology Dispensing Association, Inc. to educate oncology community about Phexxi. Evofem Biosciences, Inc. is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.84 out of 5 stars

Medical Sector

173rd out of 2,101 stocks

Pharmaceutical Preparations Industry

74th out of 831 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Evofem Biosciences (NASDAQ:EVFM) Frequently Asked Questions

Is Evofem Biosciences a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evofem Biosciences stock.
View analyst ratings for Evofem Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Evofem Biosciences?

Wall Street analysts have given Evofem Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Evofem Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Evofem Biosciences' next earnings date?

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Evofem Biosciences

How were Evofem Biosciences' earnings last quarter?

Evofem Biosciences, Inc. (NASDAQ:EVFM) posted its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.07. The biotechnology company earned $1.11 million during the quarter, compared to the consensus estimate of $2.02 million.
View Evofem Biosciences' earnings history

How has Evofem Biosciences' stock price been impacted by Coronavirus?

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVFM shares have decreased by 77.7% and is now trading at $1.15.
View which stocks have been most impacted by COVID-19

What price target have analysts set for EVFM?

4 analysts have issued 12-month price targets for Evofem Biosciences' shares. Their forecasts range from $3.00 to $25.00. On average, they expect Evofem Biosciences' share price to reach $9.25 in the next twelve months. This suggests a possible upside of 704.3% from the stock's current price.
View analysts' price targets for Evofem Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Evofem Biosciences' key executives?

Evofem Biosciences' management team includes the following people:
  • Ms. Saundra Pelletier, Pres, CEO & Director (Age 51, Pay $1.84M)
  • Mr. Justin J. File, Chief Financial Officer (Age 51, Pay $1.01M)
  • Mr. Russell Barrans, Chief Commercial Officer (Age 61, Pay $762.98k)
  • Mr. Richard Murawski, Sr. VP of Operations (Age 73)
  • Mr. Mark Kowieski, VP of Fin. & Accounting
  • Ms. Katherine Mercier, VP of Technical Operations
  • Ms. Amy Raskopf, VP of Investor Relations
  • Mr. Alexander A. Fitzpatrick Esq., Exec. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Tim Glennon, VP of Marketing
  • Kathy Gallo-Doyle, VP of Sales

Who are some of Evofem Biosciences' key competitors?

What other stocks do shareholders of Evofem Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), OrganiGram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

What is Evofem Biosciences' stock symbol?

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Who are Evofem Biosciences' major shareholders?

Evofem Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.75%), Baker BROS. Advisors LP (2.62%), Heartland Advisors Inc. (2.58%), Caas Capital Management LP (2.27%), Great Lakes Advisors LLC (2.04%) and Geode Capital Management LLC (1.29%). Company insiders that own Evofem Biosciences stock include Alexander A Fitzpatrick, Justin J File, Kelly Culwell, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier and William Walmsley Hall.
View institutional ownership trends for Evofem Biosciences

Which institutional investors are selling Evofem Biosciences stock?

EVFM stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Valeo Financial Advisors LLC, Northern Trust Corp, Commonwealth Equity Services LLC, UBS Group AG, and Nuveen Asset Management LLC.
View insider buying and selling activity for Evofem Biosciences
or view top insider-selling stocks.

Which institutional investors are buying Evofem Biosciences stock?

EVFM stock was acquired by a variety of institutional investors in the last quarter, including Caas Capital Management LP, Baker BROS. Advisors LP, Great Lakes Advisors LLC, D. E. Shaw & Co. Inc., Laurion Capital Management LP, BlackRock Inc., Point72 Asset Management L.P., and SG Americas Securities LLC. Company insiders that have bought Evofem Biosciences stock in the last two years include Alexander A Fitzpatrick, Justin J File, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Russell Barrans, Saundra L Pelletier, and William Walmsley Hall.
View insider buying and selling activity for Evofem Biosciences
or or view top insider-buying stocks.

How do I buy shares of Evofem Biosciences?

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evofem Biosciences' stock price today?

One share of EVFM stock can currently be purchased for approximately $1.15.

How much money does Evofem Biosciences make?

Evofem Biosciences has a market capitalization of $118.26 million and generates $450,000.00 in revenue each year. The biotechnology company earns $-142,310,000.00 in net income (profit) each year or ($1.56) on an earnings per share basis.

How many employees does Evofem Biosciences have?

Evofem Biosciences employs 147 workers across the globe.

What is Evofem Biosciences' official website?

The official website for Evofem Biosciences is

Where are Evofem Biosciences' headquarters?

Evofem Biosciences is headquartered at 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130.

How can I contact Evofem Biosciences?

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.